Hansa Biopharma — Juli 2022
-
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform
-
"Proceeds will be mainly utilized to:
Further strengthen the Company’s position in kidney transplantation through the continued support of ongoing European commercial launch activities for Idefirix (imlifidase) and execution of the U.S. ConfIdeS trial of imlifidase, which is expected to support a potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway in the first half of 2024. In addition, Hansa will advanc
-
Fra debatteb: https://www.proinvestor.com/boards/104550/
-
Hansa Biopharma AB: Hansa Biopharma half year report 2022
Hansa Biopharma half year report 2022
• Continued solid sales in Q2 • Positive NICE recommendation obtained • Completed
News Powered by Cision (news.cision.com)
-
Husk CC idag kl. 14:00.
The webcast will be available on:
-
Hansa Biopharma Q2; Idefirix sales progress and secured funding to end 2024
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind